Remimazolam for anesthesia and sedation in cardiac surgery and for cardiac patients undergoing non-cardiac surgery: a systematic-narrative hybrid review.
Jacopo D'Andria UrsoleoMargherita LicheriGaia BaruccoRosario LosiggioGiovanna FrauMarina PieriFabrizio MonacoPublished in: Minerva anestesiologica (2024)
Though remimazolam has demonstrated potential safety, efficacy, and ease-of-use for both anesthesia induction and maintenance in cardiac surgery patients and high-risk cardiovascular patients undergoing non-cardiac surgery, further research is imperative to delve into specific patient subgroups (e.g., the elderly or emergent procedures) so as to ascertain optimal dose ranges to suit diverse clinical scenarios.
Keyphrases
- patient reported outcomes
- cardiac surgery
- acute kidney injury
- patients undergoing
- end stage renal disease
- climate change
- chronic kidney disease
- left ventricular
- case report
- ejection fraction
- peritoneal dialysis
- newly diagnosed
- prognostic factors
- intensive care unit
- extracorporeal membrane oxygenation
- patient reported